DDInter770 DDInter596
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Fluvoxamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Fluvoxamine {u} (Compound) upregulates {v} (Gene) CCNA1
CCNA1 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Fluvoxamine {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Hyperlipidaemia
Hyperlipidaemia {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Fluvoxamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) covaries with {v} (Gene) ACADS
ACADS {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Fluvoxamine {u} (Compound) upregulates {v} (Gene) CCNA1
CCNA1 {u} (Gene) is upregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Fluvoxamine {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Hyperlipidaemia
Hyperlipidaemia {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Fluvoxamine {u} (Compound) resembles {v} (Compound) Ridogrel
Ridogrel {u} (Compound) binds {v} (Gene) TBXA2R
TBXA2R {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Fluvoxamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Fluvoxamine (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Doxorubicin (Compound)
Fluvoxamine (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Doxorubicin (Compound)
Fluvoxamine (Compound) causes Hyperlipidaemia (Side Effect) and Hyperlipidaemia (Side Effect) is caused by Doxorubicin (Compound)
Fluvoxamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Fluvoxamine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) covaries with ACADS (Gene) and ACADS (Gene) is upregulated by Doxorubicin (Compound)
Fluvoxamine (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Fluvoxamine (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Fluvoxamine (Compound) causes Hyperlipidaemia (Side Effect) and Hyperlipidaemia (Side Effect) is caused by Epirubicin (Compound) and Epirubicin (Compound) resembles Doxorubicin (Compound)
Fluvoxamine (Compound) resembles Ridogrel (Compound) and Ridogrel (Compound) binds TBXA2R (Gene) and TBXA2R (Gene) is upregulated by Doxorubicin (Compound)